<DOC>
	<DOCNO>NCT00529321</DOCNO>
	<brief_summary>The primary objective determine safety sub-cutaneous ( SC ) injection TG4040 non-cirrhotic , treatment-naïve patient chronically infect HCV ( genotype 1 ) . Patients sequentially treat escalting dose TG4040 . All patient follow least 6 month his/her first injection . In addition , patient treat high dose receive TG4040 boost injection 6 month first injection , follow additional 6-month period .</brief_summary>
	<brief_title>Immunotherapy With TG4040 Treatment-naïve Patients Chronically Infected With Hepatitis C Virus</brief_title>
	<detailed_description>The first nine patient sequentially treat three cohort three patient , i.e . receive 3 SC injection TG4040 Days 1 , 8 15 , dose 10e6 pfu ( first cohort ) , 10e7 pfu ( second cohort ) , 10e8 pfu ( third cohort ) . There one-week safety interval first injection patient give cohort , two-week safety interval last injection last patient give cohort first injection first patient next one . There also two-week safety observation period last injection last patient third cohort . If dose 10e8 pfu raise safety problem , 6 patient enrol , without safety interval patient . They receive 3 SC injection TG4040 dose 10e8 pfu , Days 1 , 8 15 . All patient follow least 6 month his/her first injection . In addition , patient treat dose 10e8 pfu receive TG4040 boost injection 6 month first injection , follow additional 6-month period . Three additional cohort 9 patient receive boost injection either 2 , 4 6 month .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Informed consent obtain sign ; Male female patient ; With chronic hepatitis C ( genotype 1 ) evidence HCV positive serology detectable 6 month ; Patients fibrosis status grade F0 F1 accord METAVIR grading system ; patient F2 fibrosis stage could enrol casebycase basis sure contraindication treat IFNbased standard HCV treatment ; patient F3 F4 fibrosis stage enrol ; assess either liver biopsy perform less 18 month prior baseline FibroTest® FibroScan® perform within 2 month prior first TG4040 injection ; case discordant result , liver biopsy perform prior TG4040 treatment ; ; Treatmentnaïve patient : patient never receive IFNbased treatment ; Patients must compensate liver disease , : No history ascites , hepatic encephalopathy bleed esophageal varix ; Laboratory test value : Serum alanine aminotransferase ( ALT ) less 2 fold Upper Limit Normal ( ULN ) ; Serum bilirubin international normalized ratio ( INR ) value within normal range ( except patient Gilbert syndrome serum bilirubin may high 3.0 mg/dL ) ; Other laboratory parameter grade 0 1 ( CTC criterion ) ; For woman childbearing potential , i.e . history hysterectomy tubal ligation , negative pregnancy test study entry adequate protection pregnancy conduct study 3 month last TG4040 injection . Additionnal cohort : Patients high ALT level ( 2 fold ULN &lt; ALT &lt; 5 fold ULN 2 month inclusion ) fibrosis high F2 . Patients exclude study follow reason : Coinfection HBV ( indicate presence Hepatitis B Surface Antigen ( HBsAg ) serum ; patient antihepatitis B core antibody response ( antiHBc ) exclude ) HIV ( antiHIV antibody serum ) ; patient HIV positive sexual partner ( history ) include ; Current HCV therapy ; Active IV drug alcohol abuse ; Serious , concomitant disorder , include : primary biliary cirrhosis sclerosing cholangitis ; autoimmune disease symptomatic cryoglobulinemia , polyarthritis , multiple sclerosis ; broad autoimmune test performed baseline ; proven suspect immunosuppressive disorder ; active systemic infection ; patient acute febrile illness ( &gt; 38°C ) day vaccination , delay least one week complete recovery ; Malignancy within last 5 year ; patient history squamous cell skin cancer basal cell skin cancer enrol , unless history skin cancer vaccination site ; Systemic corticosteroid therapy immunosuppressive/immunomodulating drug ( e.g . Cyclosporine ) within 2 month prior first study drug injection ; corticosteroid nasal spray , inhaled steroid asthma and/or topical steroid permissible ; Participation another experimental protocol study period ( last intake investigational drug within 6 month prior baseline ) ; Breastfeeding woman ; Receipt inactivate vaccine 14 day prior vaccination duration study ; receipt live attenuate vaccine within 30 day prior vaccination duration study ; Allergy egg ; Patient unable comply protocol requirement ; Any condition , opinion investigator , might interfere study objective .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>